Testing for coronavirus disease 2019 (COVID-19) before procedures has become a fixture of City of Hope's efforts to protect patients with cancer and staff, noted Harlan Levine, MD, president of Strategy and Business Ventures at City of Hope.
Testing for coronavirus disease 2019 (COVID-19) before procedures and admissions has become a fixture of City of Hope's efforts to protect patients with cancer and our staff. Additionally, there are over 2 dozen projects focusing on aspects related to better controlling the pandemic, said Harlan Levine, MD, president of Strategy and Business Ventures at City of Hope.
Transcript
AJMC®: COVID-19 has changed ways of delivering care and conducting clinical trials. What strategies has City of Hope developed to deliver best-in-class care and foster innovation during the pandemic?
Dr Levine: Our philosophy is that cancer doesn't stop for COVID-19 and neither should we. As a NCI-Designated Cancer Center taking care of immunocompromised patients, we already excel at protecting patients against infections and preventing them from happening in the first place. But the COVID pandemic has led us to reevaluate all of our processes, and we've made changes to enhance our protection of our patients, but also our staff.
Initially, we did reduce our volumes, but at no point did we stop the necessary treatments or procedures or bone marrow transplants that people needed. Currently, to protect our patients and our staff, we’re testing for COVID-19 before most procedures and admissions. We also have drive-through testing for our out-patient clinics and for staff that come to the clinic.
Like all hospitals, we've had to modify our visitor policies during the COVID-19 pandemic. From a global point of view, our scientists have contributed to the global efforts to stem this horrible pandemic. We have over 2 dozen projects that either focus on vaccines, treatments, diagnostics, or other screening tools to help us better control the pandemic.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Frameworks for Advancing Health Equity: Trans and Gender Diverse Health Care
June 28th 2024Charlie Borowicz, manager of trans and gender diverse health at Allegheny Health Network, shares how the program offers comprehensive patient-first care to those in the LGBTQ+ and gender diverse community.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More